Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC

June 10, 2019
Shirish M. Gadgeel, MD
Shirish M. Gadgeel, MD

In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.

In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, spoke with Cancer Network about the results of a phase II study (abstract 9021), which were presented at ASCO 2019. The trial focused on docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation-positive, recurrent non-small cell lung cancer.